Based on the key indicators related to VTv Therapeutics' liquidity, profitability, solvency, and operating efficiencyBased on the analysis of, vTv Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in January. At this time, VTv Therapeutics' Other Stockholder Equity is comparatively stable compared to the past year. Property Plant And Equipment Gross is likely to gain to about 1.1 M in 2024, whereas Other Current Liabilities is likely to drop slightly above 5.7 M in 2024. Key indicators impacting VTv Therapeutics' financial strength include:
The essential information of the day-to-day investment outlook for VTv Therapeutics includes many different criteria found on its balance sheet. An individual investor should monitor VTv Therapeutics' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in VTv Therapeutics.
Please note, the imprecision that can be found in VTv Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of vTv Therapeutics. Check VTv Therapeutics' Beneish M Score to see the likelihood of VTv Therapeutics' management manipulating its earnings.
VTv Therapeutics Stock Summary
VTv Therapeutics competes with DiaMedica Therapeutics, Lyra Therapeutics, and Centessa Pharmaceuticals. vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews Forbes Incorporated. Vtv Theraptcs operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 9 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
The reason investors look at the income statement is to determine what VTv Therapeutics' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining VTv Therapeutics's current stock value. Our valuation model uses many indicators to compare VTv Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across VTv Therapeutics competition to find correlations between indicators driving VTv Therapeutics's intrinsic value. More Info.
vTv Therapeutics is rated fourth in return on equity category among its peers. It is rated third in return on asset category among its peers . At this time, VTv Therapeutics' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value VTv Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
vTv Therapeutics Systematic Risk
VTv Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. VTv Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on vTv Therapeutics correlated with the market. If Beta is less than 0 VTv Therapeutics generally moves in the opposite direction as compared to the market. If VTv Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one vTv Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of VTv Therapeutics is generally in the same direction as the market. If Beta > 1 VTv Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
VTv Therapeutics Thematic Clasifications
vTv Therapeutics is part of Pharmaceutical Products investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
This theme covers USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
Today, most investors in VTv Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various VTv Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of VTv Therapeutics growth as a starting point in their analysis.
VTv Therapeutics December 2, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of VTv Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of vTv Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of vTv Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing VTv Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build VTv Therapeutics's daily price indicators and compare them against related drivers.
When running VTv Therapeutics' price analysis, check to measure VTv Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy VTv Therapeutics is operating at the current time. Most of VTv Therapeutics' value examination focuses on studying past and present price action to predict the probability of VTv Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move VTv Therapeutics' price. Additionally, you may evaluate how the addition of VTv Therapeutics to your portfolios can decrease your overall portfolio volatility.